Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.
A number of other brokerages have also recently issued reports on CNTB. Wall Street Zen raised Connect Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Canaccord Genuity Group decreased their price target on Connect Biopharma from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, September 16th. BTIG Research dropped their target price on shares of Connect Biopharma to $5.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. Oppenheimer dropped their target price on shares of Connect Biopharma to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, September 22nd. Finally, Weiss Ratings upgraded Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $6.14.
Read Our Latest Report on CNTB
Connect Biopharma Stock Up 4.3%
Connect Biopharma (NASDAQ:CNTB – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.04. The company had revenue of $2.75 million for the quarter, compared to the consensus estimate of $0.74 million. As a group, equities research analysts expect that Connect Biopharma will post -1.09 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in CNTB. Bank of America Corp DE bought a new position in shares of Connect Biopharma in the 1st quarter worth $41,000. Simplify Asset Management Inc. bought a new position in shares of Connect Biopharma in the 1st quarter worth $135,000. Richmond Brothers Inc. bought a new position in shares of Connect Biopharma in the 4th quarter worth $489,000. Knott David M Jr boosted its position in shares of Connect Biopharma by 93.9% in the 1st quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after purchasing an additional 187,835 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in shares of Connect Biopharma in the 1st quarter worth $1,945,000. 58.72% of the stock is currently owned by institutional investors.
About Connect Biopharma
Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.
Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.
Featured Stories
- Five stocks we like better than Connect Biopharma
- Constellation Brands Beat Earnings, But Beer Demand Is Still a Problem
- Tesla’s EV Delivery Beat Is In, So What Happens Now?
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
